Anadys Pharmaceuticals, Inc.
The people of Anadys are committed to advancing patient care by discovering, developing, and commercializing novel and powerful anti-infective medicines. Anadys is focused on the discovery and development of small molecule therapeutics for the treatment of infectious disease, including hepatitis C and bacterial infections. The company's lead program for the treatment of hepatitis C is currently in Phase IB testing. Anadys also has a broad portfolio of antiviral and antibacterial programs directed at novel targets, intervention points and mechanisms of action. With an integrated suite of technologies and capabilities, including Riboproteomics, ATLAS and structure-based drug design through a world-class medicinal chemistry team, Anadys is capable of quickly optimizing lead compounds for use in preclinical and clinical testing. The company's goal is to build a strong and continual pipeline of novel and powerful drug candidates directed to advance patient care.